CN114206868B - 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物 - Google Patents

作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物 Download PDF

Info

Publication number
CN114206868B
CN114206868B CN202080055779.0A CN202080055779A CN114206868B CN 114206868 B CN114206868 B CN 114206868B CN 202080055779 A CN202080055779 A CN 202080055779A CN 114206868 B CN114206868 B CN 114206868B
Authority
CN
China
Prior art keywords
pyridin
compound
trifluoromethyl
pyrrolo
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080055779.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114206868A (zh
Inventor
E·卡塞尔勒冈萨雷斯
A·奥特加穆诺茨
J·萨拉斯索拉纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oryzon Genomics SA
Original Assignee
Oryzon Genomics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics SA filed Critical Oryzon Genomics SA
Publication of CN114206868A publication Critical patent/CN114206868A/zh
Application granted granted Critical
Publication of CN114206868B publication Critical patent/CN114206868B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080055779.0A 2019-06-06 2020-06-05 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物 Active CN114206868B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382475.2 2019-06-06
EP19382475 2019-06-06
EP19383221.9 2019-12-31
EP19383221 2019-12-31
PCT/EP2020/065658 WO2020245381A1 (en) 2019-06-06 2020-06-05 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors

Publications (2)

Publication Number Publication Date
CN114206868A CN114206868A (zh) 2022-03-18
CN114206868B true CN114206868B (zh) 2025-02-25

Family

ID=71083614

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055779.0A Active CN114206868B (zh) 2019-06-06 2020-06-05 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物

Country Status (7)

Country Link
US (1) US12522598B2 (https=)
EP (1) EP3980416B1 (https=)
JP (1) JP7523146B2 (https=)
CN (1) CN114206868B (https=)
CA (1) CA3142435A1 (https=)
MX (1) MX2021014918A (https=)
WO (1) WO2020245381A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110663A1 (en) * 2017-12-05 2019-06-13 Oryzon Genomics, S.A. 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101618B2 (en) 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
US20100136024A1 (en) 2008-11-14 2010-06-03 Bartels Stephen P Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
BR112014012815A8 (pt) 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2017014170A1 (ja) 2015-07-17 2018-04-26 武田薬品工業株式会社 複素環化合物
AU2016297362B2 (en) 2015-07-17 2020-04-16 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as HDAC inhibitors
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
WO2017161033A1 (en) 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222950A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018118781A1 (en) 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110663A1 (en) * 2017-12-05 2019-06-13 Oryzon Genomics, S.A. 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

Also Published As

Publication number Publication date
MX2021014918A (es) 2022-06-27
US12522598B2 (en) 2026-01-13
WO2020245381A1 (en) 2020-12-10
JP2022535290A (ja) 2022-08-05
CN114206868A (zh) 2022-03-18
JP7523146B2 (ja) 2024-07-26
EP3980416A1 (en) 2022-04-13
US20220298156A1 (en) 2022-09-22
CA3142435A1 (en) 2020-12-10
EP3980416B1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
CN111406054B (zh) 作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物
CN108314677B (zh) 一种ezh2抑制剂及其用途
ES2316546T3 (es) 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
JP7175888B2 (ja) 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
US8486945B2 (en) Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system
TWI399380B (zh) 抗病毒化合物
JP2017537948A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
TW200417546A (en) New compounds
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
CN114206868B (zh) 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
KR20090024110A (ko) 키나제 억제제로서의 ３-치환된 Ｎ-(아릴- 또는 헤테로아릴)-피라졸로[１,５-ａ]피리미딘
CN105246887A (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
JP2022504703A (ja) ピリミジン及びピラジンｈｄａｃ１、２阻害剤
CN107743489A (zh) 用于治疗免疫疾病、炎性疾病或者癌症的7‑(吗啉‑4‑基)吡唑并[1,5‑a]嘧啶衍生物
US7714010B2 (en) Pyrrolobenzimidazolones and their use as anti-proliferative agents
EP3632912B1 (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
RU2797613C2 (ru) Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6
AU2018278284A1 (en) Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors
TWI692476B (zh) 環丁基-咪唑啶酮化合物
US20250312335A1 (en) Flt combination therapy for cancer and compositions therefor
CN121175307A (zh) Vanin-1抑制剂
JP2020186182A (ja) 標的蛋白質分解誘導化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant